BEIJING - Sinovac Biotech's booster dose for COVID-19 has shown a reduction in its deteriorating antibody response against the delta variant in a recent study.
The Sinovac vaccine's gradually decreasing antibody response had become a threat to its long term immune response to the highly contagious strain of COVID.
Before Sinovac's booster dose study, neutralising antibody response against Delta variant had not been identified in vaccine recipients six months after receiving the second dose of Sinovac's CoronaVac vaccine in a recently published study.
Now, most of the countries that have been relied on the Sinovac vaccine have started giving boosters to people fully vaccinated with the Chinese shot.
